Barclays

Barclays’s Alpha Tau Medical Warrant DRTSW Stock Holding History

Barclays’s Portfolio DRTSW Stock Details DRTSW Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-43,458	Closed	-$27K	–	5081
2022 Q1	$27K	Buy	+43,458	New	+$23.7K	﹤0.01%	4339

Other funds holding DRTSW

Radcliffe Capital Management Bala Cynwyd, Pennsylvania $1.33B AUM 1.18% 1-Year Est. Return

LMR Partners London, United Kingdom $45.4B AUM 60.68% 1-Year Est. Return

Angelo Gordon & Co New York $1.06B AUM 47.95% 1-Year Est. Return

Corbin Capital Partners New York $61.3M AUM 53.03% 1-Year Est. Return

MMCAP International Grand Cayman, Cayman Islands $1.16B AUM 77.9% 1-Year Est. Return

Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return

Polar Asset Management Partners Toronto, Ontario, Canada $5.01B AUM 35.27% 1-Year Est. Return

Walleye Capital

Walleye Capital New York $24B AUM 37.67% 1-Year Est. Return

Moore Capital Management New York $4.92B AUM 35.41% 1-Year Est. Return

Eisler Capital (UK) London, United Kingdom $21.7B AUM 0.34% 1-Year Est. Return

Barclays's DRTSW Position: Q2 2022 in Review

Barclays sold out of Alpha Tau Medical Warrant (DRTSW) in Q2 2022, closing a stake of 43,458 shares — an estimated $27K sold.

Barclays first reported a position in DRTSW in Q1 2022 and held it in 1 quarter. The position peaked at $27K in Q1 2022. 37 funds tracked by Wall St. Rank hold DRTSW as of Q2 2022.

Barclays reported no remaining Alpha Tau Medical Warrant position as of Q2 2022 after selling out during the quarter.
Barclays sold 43,458 Alpha Tau Medical Warrant shares in Q2 2022, an estimated $27K.
Barclays first reported a position in Alpha Tau Medical Warrant in Q1 2022 and held it in 1 quarter.
Barclays's Alpha Tau Medical Warrant position peaked at $27K in Q1 2022.
37 funds tracked by Wall St. Rank held Alpha Tau Medical Warrant as of Q2 2022.

Based on Barclays's 13F filing for Q2 2022, filed 12 Aug 2022.